肝动脉化疗栓塞联合射频消融治疗中晚期肝癌的疗效评价

目的探讨肝动脉化疗栓塞（TACE）联合射频消融（RFA）治疗中晚期肝癌的疗效及安全性。方法选取我院收治的中晚期肝癌患者66例按照数字表格法随机分为两组,每组33例。对照组采用TACE治疗,观察组采用TACE联合RFA治疗,观察两组患者的临床疗效及生存率。结果观察组患者的总有效率为93.94%,显著高于对照组患者的69.70%（χ2=4.991,P=0.026）。观察组患者1年、2年、3年生存率分别为90.91%、81.82%、69.70%,中位生存期为2.316年;对照组患者1年、2年、3年生存率分别为75.76%、54.55%、30.30%,中位生存期为1.752年;观察组显著高于对照组（P〈0.05）。结论 TACE联合RFA治疗中晚期肝癌临床疗效显著,可有效提高肿瘤的坏死率,改善生存质量,延长患者的生存期。

CHnical efficacy and safety of transcatheter arterial combined with radiofrequency ablation in the treatment of advanced hepatocellular carcinoma.

Objective To investigate the clinical efficacy and safety oftranscatheter arterial chemoemboliza- tion combined with radiofrequency ablation in the treatment of advanced hepatocellular carcinoma. Methods Six- ty-six patients with advanced hepatocellular carcinoma were divided into the control group and the observation group by numerical form randomly, with 33 patients in each group. The control group was given TACE treatment, while the observation group used TACE combined with RFA for treatment. The clinical efficacy and survival rate were com- pared between the two groups. Results The total effective rate was 93.94% in the observation group, significantly higher than 69.70% in the control group （Z2=4.991, P=0.026）. The survival rates of l-year, 2-year and 3-year were 90.91%, 81.82% and 69.70%, respectively, with a median survival period of 2.316 years in the observation group. The survival rates of 1-year, 2-year and 3-year were 75.76%, 54.55% and 30.30%, respectively, with a median sur- vival period of 1.752 years in the control group. There was significant difference between the two groups （P〈0.05）. Condusion The clinical effect of TACE combined with RFA in the treaanent of advanced hepatocellular carcinoma is good. It can effectively raise the tumor necrosis rate, improve the quality of life, and prolong survival of the patients.